Systemic vasculitis

Poonam K Sharma, Sanjeev Sharma, Richard Baltaro, John Hurley

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The systemic vasculitides are characterized by inflammation of blood vessel walls. Vessels of any type, in any organ can be affected, resulting in a broad spectrum of signs and symptoms. The heterogenous nature of vasculitides presents a diagnostic challenge. The American College of Rheumatology classification criteria and the Chapel Hill Consensus Conference nomenclature are the most widely used to distinguish different forms of vasculitis. The Chapel Hill Consensus Conference nomenclature defnes 10 primary vasculitides based on vessel size (large, medium, and small). The diagnosis relies on the recognition of a compatible clinical presentation supported by specific laboratory or imaging tests and confirmatory histology. Antineutrophilic cytoplasmic antibody testing has been of particular benefit in defining a subgroup of small vessel vasculitides. Treatment is based on clinical presentation and the pattern of organ involvement. Glucocorticoids are the primary treatment for many forms of vasculitis. Additional immunosuppressive agents, including methotrexate and cyclophosphamide, are sometimes required. Newer approaches, such as the use of anti-tumor necrosis factor or B cell therapies, are being tried in resistant cases. Patients can experience considerable treatment-related toxicity, especially infection from immunosuppressive therapy and adverse effects from steroids (e.g., osteoporosis, diabetes mellitus, cataract). Vitamin D and calcium prophylaxis are recommended in patients on long-term steroid therapy.

Original languageEnglish
Pages (from-to)556-565
Number of pages10
JournalAmerican Family Physician
Volume83
Issue number5
StatePublished - Mar 1 2011

Fingerprint

Systemic Vasculitis
Vasculitis
Immunosuppressive Agents
Terminology
Steroids
Therapeutics
Cell- and Tissue-Based Therapy
Methotrexate
Vitamin D
Cyclophosphamide
Cataract
Glucocorticoids
Osteoporosis
Signs and Symptoms
Blood Vessels
Histology
Diabetes Mellitus
B-Lymphocytes
Tumor Necrosis Factor-alpha
Inflammation

All Science Journal Classification (ASJC) codes

  • Family Practice

Cite this

Sharma, P. K., Sharma, S., Baltaro, R., & Hurley, J. (2011). Systemic vasculitis. American Family Physician, 83(5), 556-565.

Systemic vasculitis. / Sharma, Poonam K; Sharma, Sanjeev; Baltaro, Richard; Hurley, John.

In: American Family Physician, Vol. 83, No. 5, 01.03.2011, p. 556-565.

Research output: Contribution to journalArticle

Sharma, PK, Sharma, S, Baltaro, R & Hurley, J 2011, 'Systemic vasculitis', American Family Physician, vol. 83, no. 5, pp. 556-565.
Sharma PK, Sharma S, Baltaro R, Hurley J. Systemic vasculitis. American Family Physician. 2011 Mar 1;83(5):556-565.
Sharma, Poonam K ; Sharma, Sanjeev ; Baltaro, Richard ; Hurley, John. / Systemic vasculitis. In: American Family Physician. 2011 ; Vol. 83, No. 5. pp. 556-565.
@article{3b051d1c7f6643d38bc175f0267f7434,
title = "Systemic vasculitis",
abstract = "The systemic vasculitides are characterized by inflammation of blood vessel walls. Vessels of any type, in any organ can be affected, resulting in a broad spectrum of signs and symptoms. The heterogenous nature of vasculitides presents a diagnostic challenge. The American College of Rheumatology classification criteria and the Chapel Hill Consensus Conference nomenclature are the most widely used to distinguish different forms of vasculitis. The Chapel Hill Consensus Conference nomenclature defnes 10 primary vasculitides based on vessel size (large, medium, and small). The diagnosis relies on the recognition of a compatible clinical presentation supported by specific laboratory or imaging tests and confirmatory histology. Antineutrophilic cytoplasmic antibody testing has been of particular benefit in defining a subgroup of small vessel vasculitides. Treatment is based on clinical presentation and the pattern of organ involvement. Glucocorticoids are the primary treatment for many forms of vasculitis. Additional immunosuppressive agents, including methotrexate and cyclophosphamide, are sometimes required. Newer approaches, such as the use of anti-tumor necrosis factor or B cell therapies, are being tried in resistant cases. Patients can experience considerable treatment-related toxicity, especially infection from immunosuppressive therapy and adverse effects from steroids (e.g., osteoporosis, diabetes mellitus, cataract). Vitamin D and calcium prophylaxis are recommended in patients on long-term steroid therapy.",
author = "Sharma, {Poonam K} and Sanjeev Sharma and Richard Baltaro and John Hurley",
year = "2011",
month = "3",
day = "1",
language = "English",
volume = "83",
pages = "556--565",
journal = "American Family Physician",
issn = "0002-838X",
publisher = "American Academy of Family Physicians",
number = "5",

}

TY - JOUR

T1 - Systemic vasculitis

AU - Sharma, Poonam K

AU - Sharma, Sanjeev

AU - Baltaro, Richard

AU - Hurley, John

PY - 2011/3/1

Y1 - 2011/3/1

N2 - The systemic vasculitides are characterized by inflammation of blood vessel walls. Vessels of any type, in any organ can be affected, resulting in a broad spectrum of signs and symptoms. The heterogenous nature of vasculitides presents a diagnostic challenge. The American College of Rheumatology classification criteria and the Chapel Hill Consensus Conference nomenclature are the most widely used to distinguish different forms of vasculitis. The Chapel Hill Consensus Conference nomenclature defnes 10 primary vasculitides based on vessel size (large, medium, and small). The diagnosis relies on the recognition of a compatible clinical presentation supported by specific laboratory or imaging tests and confirmatory histology. Antineutrophilic cytoplasmic antibody testing has been of particular benefit in defining a subgroup of small vessel vasculitides. Treatment is based on clinical presentation and the pattern of organ involvement. Glucocorticoids are the primary treatment for many forms of vasculitis. Additional immunosuppressive agents, including methotrexate and cyclophosphamide, are sometimes required. Newer approaches, such as the use of anti-tumor necrosis factor or B cell therapies, are being tried in resistant cases. Patients can experience considerable treatment-related toxicity, especially infection from immunosuppressive therapy and adverse effects from steroids (e.g., osteoporosis, diabetes mellitus, cataract). Vitamin D and calcium prophylaxis are recommended in patients on long-term steroid therapy.

AB - The systemic vasculitides are characterized by inflammation of blood vessel walls. Vessels of any type, in any organ can be affected, resulting in a broad spectrum of signs and symptoms. The heterogenous nature of vasculitides presents a diagnostic challenge. The American College of Rheumatology classification criteria and the Chapel Hill Consensus Conference nomenclature are the most widely used to distinguish different forms of vasculitis. The Chapel Hill Consensus Conference nomenclature defnes 10 primary vasculitides based on vessel size (large, medium, and small). The diagnosis relies on the recognition of a compatible clinical presentation supported by specific laboratory or imaging tests and confirmatory histology. Antineutrophilic cytoplasmic antibody testing has been of particular benefit in defining a subgroup of small vessel vasculitides. Treatment is based on clinical presentation and the pattern of organ involvement. Glucocorticoids are the primary treatment for many forms of vasculitis. Additional immunosuppressive agents, including methotrexate and cyclophosphamide, are sometimes required. Newer approaches, such as the use of anti-tumor necrosis factor or B cell therapies, are being tried in resistant cases. Patients can experience considerable treatment-related toxicity, especially infection from immunosuppressive therapy and adverse effects from steroids (e.g., osteoporosis, diabetes mellitus, cataract). Vitamin D and calcium prophylaxis are recommended in patients on long-term steroid therapy.

UR - http://www.scopus.com/inward/record.url?scp=79955946812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955946812&partnerID=8YFLogxK

M3 - Article

VL - 83

SP - 556

EP - 565

JO - American Family Physician

JF - American Family Physician

SN - 0002-838X

IS - 5

ER -